This letter proposes a novel technique for detecting a target signal buried in clutter using principal component analysis (PCA) for pulse-Doppler radar systems. The conventional detection algorithm is based on the fast Fourier transform-constant false alarm rate (FFT-CFAR) approaches. However, the detection task becomes extremely difficult when the Doppler spectrum of the target is completely b...

Recently, a novel approach for PN code acquisition of direct sequence code division multipleaccess (DS-CDMA) systems in Rayleigh fading multipath channel was proposed in [1]. The authors considered a combination of adaptive thresholding constant false alarm rate (CFAR) and smart antennas to increase the system capacity and consequently enhance the detection performance. This paper considers sti...

The development of Intelligent Transportation Systems (ITS) puts forward higher requirements for millimeter-wave radar surveillance in the traffic environment, such as lower time delay, sensitivity, and better multi-target detection capability. Constant False Alarm Rate (CFAR) detector plays a vital role adaptive target radar. Still, traditional CFAR algorithms use sliding window to find limit ...

Vasoactive effects of supplemental pentobarbital anesthesia in the canine hindlimb microcirculation were documented in two groups of animals previously anesthetized with 30 mg/kg pentobarbital: Group I with a 5 mg/kg intravenous (iv) bolus of pentobarbital (n = 8) and Group II with a 5 mg/kg 2-min iv infusion of pentobarbital (n = 7). In Group I, measurements at baseline (BL) and 5, 15, 20, and...

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) is associated with superior overall survival (OS) for patients with chronic lymphocytic leukemia (CLL). Alemtuzumab (A) was added to FCR (CFAR) in a phase 2 trial for high-risk untreated patients < 70 years with serum -2 microglobulin ( 2M) > 4 mg/L. Sixty patients were enrolled; median age was 59 years (range,...

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) is associated with superior overall survival (OS) for patients with chronic lymphocytic leukemia (CLL). Alemtuzumab (A) was added to FCR (CFAR) in a phase 2 trial for high-risk untreated patients < 70 years with serum β-2 microglobulin (β2M) ≥ 4 mg/L. Sixty patients were enrolled; median age was 59 years (range...